Revolution Medicines, Inc.
RVMD
$37.01
$0.531.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 49.71% | 74.33% | 37.72% | 40.86% | 67.17% |
| Gross Profit | -49.71% | -74.33% | -38.47% | -40.86% | -234.60% |
| SG&A Expenses | 86.91% | 53.30% | 51.33% | 54.45% | 48.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.99% | 70.92% | 39.35% | 42.57% | 39.09% |
| Operating Income | -68.99% | -70.92% | -40.02% | -42.57% | -43.98% |
| Income Before Tax | -85.98% | -83.97% | -21.17% | -39.17% | -35.54% |
| Income Tax Expenses | -- | -- | -319.53% | -- | -- |
| Earnings from Continuing Operations | -85.98% | -83.97% | -20.45% | -44.13% | -35.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.98% | -83.97% | -20.45% | -44.13% | -35.54% |
| EBIT | -68.99% | -70.92% | -40.02% | -42.57% | -43.98% |
| EBITDA | -69.68% | -71.58% | -40.11% | -42.69% | -44.12% |
| EPS Basic | -62.85% | -61.08% | 2.13% | 5.64% | 12.28% |
| Normalized Basic EPS | -62.87% | -61.08% | -16.96% | 8.89% | 12.28% |
| EPS Diluted | -62.85% | -61.08% | 2.13% | 5.64% | 12.28% |
| Normalized Diluted EPS | -62.87% | -61.08% | -16.96% | 8.89% | 12.28% |
| Average Basic Shares Outstanding | 14.19% | 14.22% | 23.07% | 52.74% | 54.51% |
| Average Diluted Shares Outstanding | 14.19% | 14.22% | 23.07% | 52.74% | 54.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |